Newron Pharmaceuticals has had a constructive FDA meeting about the clinical hold on its evenamide Phase III ENIGMA-TRS 2 trial and also secured up to €38 million in funding to advance the program. The company plans to propose changes to address the FDA’s concerns, while the financing extends its cash runway beyond key 12-week results.
Newron Pharmaceuticals has secured up to €38 million in milestone-based financing from European and Asian investors to advance its Phase III ENIGMA-TRS program evaluating evenamide as an add-on therapy for treatment-resistant schizophrenia.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07773831 |
Efficacy and Safety of Temporal Interference Stimulation in Treatment-Resistant Schizophrenia: An Exploratory Study. |
NOT_YET_RECRUITING | NA |
| NCT07184619 |
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia |
RECRUITING | PHASE3 |
